- Home
- TNYA
TNYA
Tenaya Therapeutics Inc.
as 04-22-2025 4:00pm EST
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $8.60 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.39 - $4.96 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tingley Whittemore | TNYA | Chief Medical Officer | Mar 10 '25 | Sell | $0.54 | 7,398 | $3,983.08 | 180,464 | |
| Ali Faraz | TNYA | Chief Executive Officer | Mar 10 '25 | Sell | $0.54 | 9,741 | $5,244.55 | 324,461 | |
| Higa Tomohiro | TNYA | SVP, Finance | Mar 10 '25 | Sell | $0.54 | 2,482 | $1,336.31 | 101,155 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Mar 5 '25 | Buy | $0.70 | 35,714,284 | $24,999,998.80 | 49,313,559 | |
| GOEDDEL DAVID V | TNYA | Director10% Owner | Mar 5 '25 | Buy | $0.70 | 35,714,284 | $24,999,998.80 | 49,313,559 |
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
22 days ago
Tenaya highlights HCM gene therapy interim data at ACC 2025
GlobeNewswire
23 days ago
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
Insider Monkey
a month ago
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?
Insider Monkey
a month ago
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March
TipRanks
a month ago
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function
MT Newswires
a month ago
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial
Simply Wall St.
a month ago
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy
GlobeNewswire
a month ago
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Compare TNYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.